Taslimarif Saiyed is the Director and COO of C-CAMP, Centre for Cellular and Molecular Platforms. In this role, he manages C-CAMP's technology platforms, growth strategies, strategic collaborations for new technology creation, education and training programmes, business and innovation accelerator unit. He also oversees the Intellecutual Property and Technology Transfer Office at C-CAMP.
Prior to joining C-CAMP, he worked as a Scientist with University of California, San Francisco (UCSF), studying neurodegenerative diseases like Parkinson's disease. He holds a doctorate in Neuroscience from Max-Planck Institute for Brain Research, Germany.
In the bay area, he also served as a Management Consultant with QB3 New Biotech Venture Consulting as well as in an individual capacity where he consulted for biotech firms in the US.
Conference Day 1 @ 09:30
Boardroom panel: Creating a robust ecosystem for pharma in India
India is poised to become a top 5 global pharmaceutical hub by 2020. But in order to achieve this, there’s work to be done, to develop a successful ecosystem. Key stakeholders including the government, pharma, regulators and investors need to work closely together to build it. In this panel, we gather them to explore how, as we explore issues including:
- How will the creation of new pharma clusters across India help enhance the ecosystem?
- How is the Indian government playing an active role to help build up the ecosystem? (Building infrastructure, funding of incubators and accelerators, mission mode programmes)
- Should a robust and sustainable ecosystem be centred around academic institutes to increase collaboration?
- What are some existing models which India can emulate? (Boston,SF Bay area, Singapore, BioValley)
- Is achieving that too idealistic? How far is India from achieving that?
Conference Day 2 @ 09:10
An organised approach to promoting nation-wide innovation
When it comes to encouraging innovation centers in India, the government has a more decentralised approach where states have the flexibility and funds to build individual programs and innovation centers to promote the growth of biotech hubs. However, sometimes too many cooks may end up spoiling the broth. So how do different government units truly measure the real return of investment of these expenditures, and how do stakeholders work together in organising a more united approach to instilling real innovation within India?
Conference Day 2 @ 11:15
Chair’s opening remarks